Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Uveal Melanoma 1Osteosarcoma 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × CR011-vcMMAE × Clear all
NCT02487979 2022-01-18

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 15 charts
Sarcoma

Osteosarcoma

NCT02363283 2020-08-21

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 12 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡